Clinical Trial Update: Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating bone mineral density changes in HIV-positive females with osteopenia who switch to raltegravir; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Osteopenia

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: Giovanni Di Perri | Conditions: HIV Infection, Osteopenia | Phase 4 | Status: TERMINATED